Henry Schein, Inc. (NASDAQ:HSIC) Shares Acquired by GAMMA Investing LLC

GAMMA Investing LLC lifted its position in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 9,339.5% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 269,782 shares of the company's stock after buying an additional 266,924 shares during the quarter. GAMMA Investing LLC owned approximately 0.22% of Henry Schein worth $184,770,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of HSIC. Palestra Capital Management LLC purchased a new stake in Henry Schein in the 4th quarter worth $182,988,000. Lyrical Asset Management LP purchased a new stake in Henry Schein in the 4th quarter worth $126,655,000. Norges Bank purchased a new stake in Henry Schein in the 4th quarter worth $103,301,000. Steadfast Capital Management LP lifted its stake in Henry Schein by 254.2% in the 4th quarter. Steadfast Capital Management LP now owns 1,637,808 shares of the company's stock worth $113,336,000 after purchasing an additional 1,175,408 shares in the last quarter. Finally, Hudson Bay Capital Management LP lifted its stake in Henry Schein by 102.1% in the 4th quarter. Hudson Bay Capital Management LP now owns 1,465,007 shares of the company's stock worth $101,378,000 after purchasing an additional 740,007 shares in the last quarter. Hedge funds and other institutional investors own 96.62% of the company's stock.

Insiders Place Their Bets

In other news, Director Philip A. Laskawy sold 2,604 shares of the company's stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total value of $184,988.16. Following the completion of the sale, the director now owns 24,805 shares of the company's stock, valued at approximately $1,762,147.20. This represents a 9.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bradford C. Connett sold 4,036 shares of the company's stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total transaction of $287,161.40. Following the completion of the sale, the chief executive officer now directly owns 62,688 shares of the company's stock, valued at $4,460,251.20. The trade was a 6.05% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.08% of the company's stock.

Henry Schein Trading Up 0.1%

NASDAQ:HSIC traded up $0.08 during mid-day trading on Thursday, hitting $70.47. 865,137 shares of the stock traded hands, compared to its average volume of 1,684,179. The stock has a market capitalization of $8.58 billion, a price-to-earnings ratio of 29.00, a PEG ratio of 2.13 and a beta of 0.87. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $82.49. The firm's 50 day moving average is $67.75 and its two-hundred day moving average is $71.66. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46.

Henry Schein (NASDAQ:HSIC - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.11 by $0.04. The company had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.24 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The firm's revenue was down .1% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.10 EPS. On average, equities research analysts predict that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. UBS Group decreased their price target on shares of Henry Schein from $83.00 to $80.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 26th. Wall Street Zen downgraded shares of Henry Schein from a "buy" rating to a "hold" rating in a report on Thursday, April 17th. Barrington Research reduced their target price on shares of Henry Schein from $90.00 to $86.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. Wells Fargo & Company reduced their target price on shares of Henry Schein from $80.00 to $75.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Finally, Piper Sandler reduced their target price on shares of Henry Schein from $83.00 to $77.00 and set an "overweight" rating on the stock in a report on Wednesday, April 30th. Six research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Henry Schein has an average rating of "Moderate Buy" and an average price target of $79.30.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.